RASolve 301
Clinician commentary on RASolve 301 in the sources reviewed for this edition leads to one open question: Does daraxonrasib deliver a durable, tolerable advantage over docetaxel, and which subtype and sequencing uncertainties will the evidence resolve? Its leading findings: (1) optimism remains conditional on clearing the docetaxel evidence threshold. (2) the safety debate depends on attribution, population and the burden of staying on treatment. (3) the most clinically attractive subgroup is also the focus of methodological skepticism. 4 more findings follow. 36 sources screened, 24 cited; not all HCPs or all public discussion.
- NCT06881784 ↗
- v1.0.0 · edition 1
- updated Oct 29, 2026
- Focused
7 findings, and what sits behind each
01. Optimism remains conditional on clearing the docetaxel evidence threshold
15 statements · 13 passages · 8 sources · 7 named voices
Counterview: recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: The comparison, Design and conduct, Primary endpoint: Overall survival (OS) in the RAS G12X-C population, Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C), Secondary endpoints, Safety and tolerability, Population and setting.
02. The safety debate depends on attribution, population and the burden of staying on treatment
23 statements · 25 passages · 8 sources · 8 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Primary endpoint: Overall survival (OS) in the RAS G12X-C population, The comparison, Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C), Secondary endpoints, Design and conduct.
03. The most clinically attractive subgroup is also the focus of methodological skepticism
29 statements · 34 passages · 12 sources · 9 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Secondary endpoints, Primary endpoint: Overall survival (OS) in the RAS G12X-C population, Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C), The comparison, Population and setting, Safety and tolerability, Design and conduct.
04. The 200 mg choice is interpreted as dose optimization rather than maximal dosing
10 statements · 13 passages · 9 sources · 7 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Safety and tolerability, Secondary endpoints, Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C), Primary endpoint: Overall survival (OS) in the RAS G12X-C population, The comparison, Design and conduct.
05. Broader RAS targeting generates enthusiasm but leaves subtype, CNS and sequencing questions open
19 statements · 20 passages · 10 sources · 9 named voices
Counterview: recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: Population and setting, Secondary endpoints, Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C), Primary endpoint: Overall survival (OS) in the RAS G12X-C population, The comparison, Safety and tolerability, Design and conduct.
06. Trial access, guideline reporting and approval must remain separate messages
7 statements · 11 passages · 4 sources · 3 named voices
Counterview: none recorded · Limitations recorded: 3. Feeds the Medical Affairs question.
Draws on: The comparison, Design and conduct.
07. Combination enthusiasm is largely relayed rationale, not established NSCLC combination evidence
4 statements · 4 passages · 3 sources · 3 named voices
Counterview: none recorded · Limitations recorded: 2. Feeds the Medical Affairs question.
Draws on: Secondary endpoints, Safety and tolerability.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 7
Optimism remains conditional on clearing the docetaxel evidence threshold
- statements
- 15
- passages
- 13
- sources
- 8
- named voices
- 7
What the statements areViews 8Questions and uncertainty 2Clinical experience 0Comparisons 2Restated results and context 3How passages are usedSupporting a statement 15Giving context 1Recorded with the finding- Counterview: recorded
- Limitations: 2
- Feeds the Medical Affairs question
- 7 posts and articles
- 1 podcast or video
Draws on: The comparison, Design and conduct, Primary endpoint: Overall survival (OS) in the RAS G12X-C population, Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C), Secondary endpoints, Safety and tolerability, Population and setting.
In the full report: the interpretation in full, all 15 statements cited to source and date, and the 8 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full RASolve 301 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
Does daraxonrasib deliver a durable, tolerable advantage over docetaxel, and which subtype and sequencing uncertainties will the evidence resolve?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 36HCP commentary sources screened
- 24sources cited by verified HCP statements
- 11found in screened sources
- 11voices cited in the report
- 9cited voices matched to verified clinician profiles
Also in the sources: 7 organizational or shared accounts, not counted as people.
- 97verified statements, each linked to its source
- 13of them from speakers with a confirmed clinical role
- 7findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Focused) is set by the 97 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians. A confirmed clinical role is one verified by the NPI registry or by the person's own institution's staff page; a role a source only states is not counted.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 97 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 24 | Counts free |
| Speaker attribution for cited voices | 11 | Paid |
Trial aspects
14 discussed · 0 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C) | 9 | 9 |
| Primary endpoint: Overall survival (OS) in the RAS G12X-C population | 10 | 9 |
| Secondary endpoints | 16 | 11 |
| Population and setting | 13 | 8 |
| The comparison | 16 | 11 |
| Safety and tolerability | 25 | 9 |
| Design and conduct | 7 | 6 |
| Dose optimization and the interpretation of 200 mg | 10 | 9 |
| Post-G12C-inhibitor sequencing, CNS activity and resistance | 8 | 5 |
| Clinical meaning of active-state, multi-selective RAS targeting | 8 | 4 |
| Credibility and generalizability of the early-phase subgroup | 20 | 5 |
| Patient support, rash prevention and sustained treatment | 10 | 2 |
| Local trial availability, guideline reporting and regulatory access | 8 | 4 |
| Combination rationale versus regimen-specific clinical evidence | 3 | 3 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 27 | 18 | |
| LinkedIn posts | 4 | 4 | |
| Bluesky threads | 4 | 1 | |
| YouTube | 1 | 1 |
max 26 / quarter
- Screened window
- Mar 27, 2025 → Oct 13, 2026
- Cited window
- Mar 27, 2025 → Oct 13, 2026
- Retrieved
- Oct 29, 2026
The trial
from ClinicalTrials.gov- Title
- RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
- Registry
- NCT06881784
- Study IDs
- RMC-6236-301
- Sponsor
- Revolution Medicines, Inc.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 590 estimated
- Start
- 2025-05-06 actual
- Primary completion
- 2027-12-01 estimated
- Primary endpoint
- Progression free survival (PFS) per Blinded Independent Central Review (BICR) in the RAS G12X-C population (i.e RAS G12X excluding G12C)
- Interventions
- 2 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on antitumor activity and dose-dependent response in previously treated RAS-mutant non-small cell lung cancer.
- Not yet captured in this edition: a view on the evidence needed to validate daraxonrasib’s response signal in previously treated advanced RAS-mutant NSCLC.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 20 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The discussion summarized here does not establish the prevalence of any view among HCPs. Social posts, repeated material and third-party relays cannot be counted as independent clinician endorsements.
- Some potentially relevant posts and video passages were not fully assessed. Discussion using different names, spellings or no trial name may be underrepresented.
- No protocol or results publication for NCT06881784 was available. The efficacy and safety results discussed by the authors are earlier-phase findings, not RASolve 301 outcomes.
- The identity of several public authors is unverified, and some clinical roles or displayed credentials are not confirmed. The educational video cannot be attributed to named HCPs.
- Official regulatory and guideline documents were not available to confirm the reported approval, guideline and reimbursement statements. Those statements remain attributed to their sources and dates.
- Early efficacy, durability, safety and discontinuation figures differ in population, dose or definition across sources. The report does not harmonize them into a common dataset or resolve numerical inconsistencies.
- Post dates do not independently establish presentation or readout dates, changing opinions or disagreement across clinical settings.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. RASolve 301 (NCT06881784): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/rasolve-301-nct06881784
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "RASolve 301" (NCT06881784), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "rasolve-301-06881784". If you cannot make requests, read https://www.erudio.com/reports/rasolve-301-nct06881784.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06881784", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06881784 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/rasolve-301-nct06881784.json
curl https://www.erudio.com/reports/rasolve-301-nct06881784.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "rasolve-301-06881784" })release 7342ec228c58be7f15a80f5b0fe06a86eaf85b87a88a5dad36f7bd28cd685c20